AOD-9604, a C-terminal fragment of human growth hormone associated with selective lipolytic activity, is paired with Tirzepatide's dual GIP and GLP-1 receptor agonism for appetite regulation and energy balance. The combination is explored for addressing fat reduction through complementary peripheral and central mechanisms.
Mechanism
Dual GIP/GLP-1 receptor agonist researched for significant appetite reduction, caloric intake suppression, and metabolic regulation contributing to body weight reduction.
C-terminal hGH fragment (176–191) researched for stimulating lipolysis and inhibiting lipogenesis without affecting insulin sensitivity or promoting growth-related systemic effects.
Dual-pathway activation
Tirzepatide × AOD-9604
Tirzepatide carries a well-characterized gastrointestinal side-effect profile in clinical research, including nausea and appetite suppression. AOD-9604 is generally reported as well-tolerated in Phase II human trials. No formal combination safety or efficacy data exists.
Per-component source only — no combination study exists
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
Metabolic effects of AOD9604: a modified fragment of human growth hormone
A mitochondrial-targeted combination pairing two peptides with distinct but complementary mechanisms. MOTS-c enhances glucose metabolism and AMPK signaling while SS-31 (Elamipretide) stabilizes cardiolipin in the inner mitochondrial membrane, protecting against oxidative damage. Researched in contexts of aging, metabolic dysfunction, and exercise performance.
A dual-mechanism fat loss stack combining semaglutide's appetite suppression and GLP-1-mediated metabolic benefits with tesamorelin's targeted visceral fat reduction through GHRH agonism. Semaglutide promotes a sustained caloric deficit and improves insulin sensitivity, while tesamorelin specifically mobilises deep abdominal visceral adipose tissue by stimulating pulsatile GH release. The two agents operate through entirely non-overlapping pathways and address different fat compartments.
Hexarelin is one of the most potent synthetic GHRP compounds, associated with robust GH release and additional cardioprotective receptor activity. Mod GRF 1-29 (CJC-1295 without DAC) is a truncated GHRH analog that provides pulsatile GH stimulation without pituitary desensitization. This pairing is commonly researched for maximizing GH secretion through complementary GHRH and GHRP receptor activation.
⚠ Educational Use OnlyPeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Newsletter
The Peptide Research Digest
New providers, emerging stacks, and research developments — weekly.